Cipher Pharmaceuticals Inc.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Cipher Pharmaceuticals Inc. (TSX:CPH; OTCQX:CPHRF) is a specialty pharmaceutical company focused on dermatology and related therapeutic areas that acquires, develops and commercializes innovative products addressing unmet medical needs; the company markets its portfolio directly in Canada and the United States or through partners in other regions including South America. Cipher offers a diversified range of commercial products including dermatology treatments Epuris (isotretinoin oral capsules for severe acne), Actikerall (topical solution for actinic keratosis), Vaniqa (topical cream for unwanted facial hair) and Natroba (spinosad topical suspension for head lice and scabies); hospital acute care offerings Aggrastat (tirofiban hydrochloride anti-platelet injection) and Brinavess (vernakalant hydrochloride for atrial fibrillation conversion); pain management product Durela (tramadol hydrochloride extended-release capsules); as well as licensing revenue from out-licensed partners on Absorica (isotretinoin), Lipofen (fenofibrate) and ConZip (tramadol). Founded in 2004 and headquartered in Mississauga, Ontario, Cipher operates primarily in North America with partnerships extending to Europe, Latin America and other markets; subsidiaries include U.S.-based entities supporting Natroba commercialization. Recent developments include the July 2024 acquisition of global rights to Natroba and its authorized generic Spinosad from ParaPRO LLC for $89.3 million (comprising $80 million cash funded by $40 million from cash reserves and $40 million from a new credit facility, plus $9.3 million in shares), along with the acquired U.S. commercial sales team; entry into a $65 million revolving credit facility (plus $25 million accordion option) with National Bank of Canada in July 2024, replacing a prior Royal Bank facility; leadership changes with Bryan Jacobs assuming the President role in October 2024 to oversee U.S. integration and Ryan Mailling appointed CFO, plus Hamed Ghanei as Chief Business Officer; and commencement of OTCQX trading under CPHRF in January 2024 to enhance U.S. investor access.
Cipher Pharmaceuticals Inc. (CPH:CA) Q1 2026 Earnings Call Transcript
CaryHealth Launches Direct-to-Patient Program for Cipher Pharmaceuticals' Natroba™ (spinosad)
Cipher Pharmaceuticals (OTCMKTS:CPHRF) Stock Price Crosses Above 50 Day Moving Average – Should You Sell?
Cipher Pharmaceuticals Inc. (CPH:CA) Q4 2025 Earnings Call Transcript
Cipher Pharmaceuticals (OTCMKTS:CPHRF) Stock Price Passes Above Fifty Day Moving Average – Should You Sell?
Cipher Pharmaceuticals Inc. (CPH:CA) Q3 2025 Earnings Call Transcript
Halvio Capital Q3 2025 Position Updates
Cipher Pharmaceuticals Inc. (CPHRF) Q2 2025 Earnings Call Transcript
Cipher Pharmaceuticals Inc. (CPHRF) Q1 2025 Earnings Call Transcript
Most Topical Earnings Summaries And Commentary For April 2025
Cipher Pharmaceuticals Inc. (CPHRF) Q4 2024 Earnings Call Transcript
Cipher Pharmaceuticals Inc. (CPHRF) Q1 2024 Earnings Call Transcript
Cipher Pharmaceuticals Announces Participation in the 2024 Bloom Burton & Co. Healthcare Investor Conference
Cipher Pharmaceuticals Inc. (CPHRF) Q3 2023 Earnings Call Transcript
Cipher Pharmaceuticals Inc. (CPHRF) Q2 2023 Earnings Call Transcript
Cipher Pharmaceuticals Inc. (CPHRF) Q4 2022 Earnings Call Transcript
Cipher Pharmaceuticals Inc. (CPHRF) Q3 2022 Earnings Call Transcript